Roche Holding AG
0QQ6.L
London Stock Exchange339.38
CHF
-3.05
- -
Roche Holding AG
0QQ6.L
(London Stock Exchange)
Recent
price
339.38
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Roche Holding AG is a Swiss multinational healthcare company primarily engaged in the research, development, and manufacture of pharmaceutical and diagnostic products. Its core offerings encompass prescription medicines targeting oncology, immunology, ophthalmology, neuroscience, infectious diseases, and metabolic disorders; diagnostics products including blood glucose meters, point-of-care testing devices, high-throughput analyzers, clinical reagents, and molecular diagnostics tools; and life science research instruments. The company operates through two main divisions: Pharmaceuticals and Diagnostics, with subsidiaries including Genentech, Chugai Pharmaceutical, Ventana, and Foundation Medicine. Roche serves global markets across Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand, headquartered in Basel, Switzerland, and founded in 1896. Recent strategic developments include the acquisition of 89bio in October 2025 for $3.5 billion, expanding its portfolio in liver and cardio-metabolic therapies, and a $2.1 billion partnership agreement through its Genentech subsidiary with Orionis Biosciences for cancer protein degrader development. Roche also completed a $1.5 billion acquisition of Poseida Therapeutics to strengthen its presence in autoimmune diseases. In 2024, it launched two innovative drugs: Itovebi (inavolisib) targeting hard-to-treat breast cancer and PiaSky (crovalimab) for paroxysmal nocturnal hemoglobinuria (PNH). Furthermore, Roche obtained FDA clearance for its first point-of-care test diagnosing whooping cough and other Bordetella infections, marking further expansion in its diagnostics portfolio. The company continues to optimize its R&D pipeline, discontinuing certain early-stage candidates while focusing on high-scientific-value assets aligned with its therapeutic priorities in cardiovascular metabolism, oncology, neurology, immunology, and ophthalmology. Roche’s diagnostics business is organized into five key units: Roche Applied Science, Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics, with a focus on health care applications for physicians, hospitals, clinics, and consumers. The company’s pharmaceutical segment encompasses patented innovative medicines and biologics, supporting treatment across multiple critical therapeutic areas. Overall, Roche maintains a leading position in cancer treatments globally and remains committed to delivering life-changing healthcare innovations through strategic acquisitions, robust pipeline management, and global reach. This comprehensive operational and strategic profile reflects Roche's ongoing commitment to scientifically driven healthcare solutions and its global footprint in pharmaceuticals and diagnostics.